What is Bupropion (Bupron)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is Bupropion (Bupron)?

Bupropion is an atypical antidepressant that functions as a norepinephrine and dopamine reuptake inhibitor, FDA-approved for treating major depressive disorder and as a smoking cessation aid. 1

Mechanism of Action

Bupropion is chemically unrelated to tricyclic antidepressants, SSRIs, or other conventional antidepressants—it belongs to the aminoketone class. 1 Unlike virtually all other antidepressants available in the United States, bupropion has no appreciable activity on serotonin neurotransmission. 2 Instead, it:

  • Inhibits reuptake of norepinephrine and dopamine in the central nervous system 2, 3
  • Acts as an inhibitor of nicotinic acetylcholinergic receptors, which explains its efficacy for smoking cessation 4
  • Produces three active metabolites (hydroxybupropion, threohydrobupropion, and erythrohydrobupropion) that contribute substantially to its antidepressant activity 2

FDA-Approved Indications

Bupropion has two primary FDA-approved uses:

  1. Major depressive disorder - Originally approved as an antidepressant 4, 1
  2. Smoking cessation - The first non-nicotine medication licensed for this purpose 5

Available Formulations

Bupropion comes in three oral formulations, all bioequivalent in terms of systemic exposure: 3

  • Immediate Release (IR): Administered three times daily 3
  • Sustained Release (SR): Administered twice daily, typically 150 mg twice daily (300 mg total) 6, 3
  • Extended Release (XL): Administered once daily, typically 300 mg in the morning 6, 3

Dosing Protocols

For Major Depressive Disorder:

  • Start with 150 mg once daily for 3 days, then increase to 150 mg twice daily (SR formulation) 6
  • Maximum dose: 450 mg per day (XL formulation) or 400 mg per day (SR formulation) to minimize seizure risk 6, 2

For Smoking Cessation:

  • Begin 1-2 weeks before the target quit date to establish therapeutic drug levels 6, 7
  • Dosing: 150 mg once daily for 3 days, then 150 mg twice daily (300 mg total) 7
  • Treatment duration: 7-12 weeks, with efficacy assessed after this period 7
  • May extend to 6-12 months in successful quitters to prevent relapse 7

Clinical Efficacy

Depression:

  • Comparable efficacy to SSRIs and tricyclic antidepressants in treating major depressive disorder 3, 8
  • Onset of action: 2 weeks, with full efficacy at 4 weeks 2
  • Particularly beneficial for patients with comorbid depression and nicotine dependence, addressing both conditions simultaneously 9, 4

Smoking Cessation:

  • Superior abstinence rates compared to placebo (OR 2.07; 95% CI 1.75-2.45) 9
  • Similar efficacy to nicotine patch but less effective than varenicline 9
  • May be especially beneficial for smokers with depression history 9, 7

Critical Safety Concerns

Seizure Risk (Most Serious):

  • Seizure incidence: 0.1% with proper dosing 4
  • Bupropion lowers the seizure threshold and must be gradually titrated 2
  • Contraindicated in patients with: 7, 1
    • Current or prior seizure disorder
    • Brain metastases or CNS tumors
    • Eating disorders (anorexia nervosa or bulimia)
    • Abrupt discontinuation of alcohol or sedatives

Other Contraindications:

  • MAOI use within 14 days (allow 2-week washout period) 1
  • Concurrent tamoxifen use 6
  • Closed-angle glaucoma 7

Common Side Effects:

  • Disturbed sleep, dry mouth, headaches, nausea 9, 7
  • Agitation, constipation, tremor 2
  • Notably causes less sexual dysfunction and weight gain compared to SSRIs 3, 8

Monitoring Requirements:

  • Neuropsychiatric symptoms (depression, suicidal ideation), especially in patients under 24 years 6, 7
  • Blood pressure monitoring - can cause hypertension, particularly when combined with nicotine replacement therapy 1
  • Evaluate response after 4 weeks of treatment 7

Special Population Considerations

Hepatic Impairment:

  • Maximum 150 mg daily for moderate to severe hepatic impairment 6

Renal Impairment:

  • Reduce total daily dose by half for moderate to severe renal impairment (GFR <90 mL/min), as bupropion metabolites accumulate 6

Older Adults:

  • Start with 37.5 mg every morning, gradually increasing by 37.5 mg every 3 days 6
  • Maximum 300 mg total daily (150 mg twice daily) 6
  • Administer second dose before 3 p.m. to minimize insomnia 6

Pregnancy and Breastfeeding:

  • Passes into breast milk - discuss risks/benefits with patients 1
  • Pregnancy registry available at 1-844-405-6185 1

Clinical Advantages

Bupropion offers distinct advantages over other antidepressants:

  • No sexual dysfunction - a major advantage over SSRIs 3, 8
  • Weight loss rather than weight gain 2, 8
  • Dual benefit for depression and smoking cessation 4, 5
  • Can be used as augmentation therapy when SSRIs fail, with superior efficacy compared to buspirone 4

Key Clinical Pearls

  • The insoluble shell of XL tablets may appear intact in stool - this is normal and does not indicate malabsorption 1
  • Longer treatment duration helps prevent relapse in successful quitters 9
  • Combination with NRT shows mixed evidence for superior efficacy, though it increases hypertension risk 9, 1
  • Highly nicotine-dependent smokers may experience rebound depression when bupropion is discontinued 10

References

Research

Other Antidepressants.

Handbook of experimental pharmacology, 2019

Guideline

Bupropion and Buspirone Clinical Use

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Bupropion Dosing and Administration

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Bupropion Treatment for Smoking Cessation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Effect of bupropion on depression symptoms in a smoking cessation clinical trial.

Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors, 2004

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.